Report: Monoclonal antibodies set to drive drug-delivery growth

Monoclonal antibodies are designed to seek out and destroy particular cancer cells, no matter where they're found in the body. According to the market research firm Kalorama Information, a new group of monoclonal antibodies will come on the market in the coming years, driving growth in drug delivery systems, BiotechDaily.com reports.

"Monoclonal antibodies represent one of the largest classes of biotechnological drugs being developed. Several products are currently on the market and many more are expected within the next few years," said Bruce Carlson, publisher of Kalorama Information. "While you won't see the double digit growth that you saw in past years in this area, monoclonal antibodies remain an important part of this multibillion dollar market."

The publication names Roche as "the clear leader in the market," since it involved in the marketing and distribution of the top five: Avastin, Herceptin, Lucentis, Rituxan and Xolair. Abbott, Pfizer and Novartis are all companies with monoclonal products in development, the publication reports.

- read more at BioTechDaily.com

Suggested Articles

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.